ÖZ
Parazitler genellikle zararlı yönleri ile bilinen canlılardır. Parazitlerin zararlarının yanında yararlı yönleri de keşfedilmiş ve halen günümüzde keşfedilecek birçok yararlı yönü bulunmaktadır. İyileşmeyen yaralarda, cerrahi operasyon sonrası yaralarda, obezite ve glikoz metabolizması bozukluklarında, sinir onarımında, kanser tedavilerinde hatta doğurganlık üzerine yararlı etkileri olduğu bildirilmiştir. Helmintlerin, protozoonların ve artropodların, parazitin kendisi ya da salgıladığı molekülleri hatta yumurtaları ile belirli bozuklukları düzeltebildiği, engelleyebildiği ve iyileştirebildiği kanıtlanmıştır. Bu yazıda parazitlerin yararlı yönleri ile alakalı çalışmalara yer verilmiştir. Parazitlerin birçoğunun bağışıklık sistemini uyarması ya da etkilemesi ile yarar sağladığı mekanizmaları anlamak ve terapötik amaçla kullanılabilmesini sağlamak için çok daha fazla çalışmaya ihtiyaç vardır.
Anahtar Kelimeler: Parazitlerin faydaları, maggot terapi, hirudo terapi, parazitomimetikler, askarozitler
References
1
Tınar R, Umur Ş, Köroğlu E, Güçlü F, Ayaz E, Şenlik B. Veteriner Helmintoloji. Dora Yayıncılık; 2011.
2
Gazzinelli-Guimaraes PH, Nutman TB. Helminth parasites and immune regulation. F1000Res 2018; 7: F1000 Faculty Rev-1685.
3
Goto Y, Nagai K. Parasitomimetics: can we utilize parasite-derived immunomodulatory molecules for interventions to immunological disorders?. Frontiers in Immunol. 2022; 1203.
4
İpek DN. Diyarbakır ve Çevresinde Eksternal Myiasis Vakaları, Bazı Parametreler ve Tedavileri ile Etkenlerin Yayılışı, Mevsimsel Aktiviteleri ve Biyolojileri Üzerine Araştırmalar Doktora Tezi, Fırat Üniv. Sağ. Bil. Enst. Parazitol Anabilim Dalı. Elazığ. 2010.
5
Yaman M, Zerek A. Miyaz Sinekleri Larvalarının yara tedavisinde kullanılması. Mustafa Kemal Üniv Tıp Derg. 2017; 8: 20-8.
6
Sherman RA. Maggot therapy for foot and leg wounds. The Int J Lower Extremity Wounds. 2002; 1: 135-42.
7
Wolff H, Hansson C. Rearing larvae ofLuciliasericata for chronic ulcer treatment–an improved method. Acta Derm Venereol. 2005; 85: 126-31.
8
Jones G, Wall R. Maggot-therapy in veterinary medicine. Res Vet Sci. 2008; 85: 394-8.
9
Sherman RA. A new dressing design for use with maggot therapy. Plast Reconstr Surg. 1997; 100: 451-6.
10
Özalp AH. Deneysel Nekrotizan Pankreatitte Maggot Terapi (Larva Debritman Tedavisi). Uzmanlık Tezi, Konya: Necmettin Erbakan Üniv. Meram Tıp Fakültesi Genel Cerrahi Anabil Dalı. 2013.
11
Shi E, Shofler D. Maggot debridement therapy: a systematic review. British J of Com Nurs. 2014; 19(Suppl 12): S6-13.
12
Grassberger M, Sherman RA, Gileva OS, Kim CM, Mumcuoglu KY. Biotherapy—history, principles and practice. Springer Dordrecht Heidelberg New York London; 2013; 37: 38-9.
13
Kerridge A, Lappin‐Scott H, Stevens JR. Antibacterial properties of larval secretions of the blowfly, Luciliasericata. Med Vet Entomol. 2005; 19: 333-7.
14
Jaklič D, Lapanje A, Zupančič K, Smrke D, Gunde-Cimerman N. Selective antimicrobial activity of maggots against pathogenic bacteria. J Med Microbiol. 2008; 57: 617-25.
15
Harris LG, Nigam Y, Sawyer J, Mack D, Pritchard DI. Lucilia sericata chymotrypsin disrupts protein adhesin-mediated staphylococcal biofilm formation. Appl Environ Microbiol. 2013; 79: 1393-5.
16
Bohova J, Majtan J, Majtan V, Takac P. Selective Antibiofilm Effects of Lucilia sericata Larvae Secretions/Excretions against Wound Pathogens. Evid Based Complement Alternat Med. 2014; 2014: 857360.
17
Cazander G, Schreurs MW, Renwarin L, Dorresteijn C, Hamann D, Jukema GN. Maggot excretions affect the human complement system. Wound Repair Regen. 2012; 20: 879-86.
18
Cazander G, Pritchard DI, Nigam Y, Jung W, Nibbering PH.Multiple actions of Luciliasericata larvae in hard‐to‐heal wounds: Larval Secretions Contain Molecules That Accelerate Wound Healing, Reduce Chronic Inflammation and Inhibit Bacterial Infection. Bioessays. 2013; 35: 1083-92.
19
Mory RN, Mindell D, Bloom DA. The leech and the physician: biology, etymology, and medical practice withHirudineamedicinalis. World J Surg. 2000; 24: 878-83.
20
Siddall ME, Trontelj P, Utevsky SY, Nkamany M, Macdonald KS. Diverse molecular data demonstrate that commercially available medicinal leeches are notHirudo medicinalis. Proc Biol Sci. 2007; 274: 1481-7.
21
Whitaker IS, Izadi D, Oliver DW, Monteath G, Butler PE.Hirudo medicinalis and the plastic surgeon. Br J Plast Surg. 2004; 57: 348-53.
22
Whitaker IS, Rao J, Izadi D, Butler PE. Historical Article: Hirudo medicinalis: ancient origins of, and trends in the use of medicinal leeches throughout history. Br J Oral Maxillofac Surg. 2004; 42: 133-7.
23
Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, et al.“Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial.” J Allergy Clin Immunol. 2010; 125: 123-30.
24
Voldsgaard A, Bager P, Garde E, Åkeson P, Leffers AM, Madsen CG, et al.Trichurissuis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler J. 2015; 21: 1723-9.
25
Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005; 128: 825-32.
26
Summers RW, Elliott DE, Urban Jr JF, Thompson RA, Weinstock JV.Trichurissuis therapy in Crohn’s disease. Gut 2005; 54: 87-90.
27
Bruschi F. (Ed.).Trichinella and Trichinellosis. Elsevier. 2021.
28
Bruschi F, Ashour DS, Othman AA.Trichinella-induced immunomodulation: Another tale of helminth success. Food Waterborne Parasitol. 2022; 27: e00164.
29
Rzepecka J, Harnett W. Can the Study of Parasitic Helminths Be Fruitful for Human Diseases? In Helminth Infections and their Impact on Global Public Health. Springer. 2022; 607-40.
30
Cheng Y, Yu Y, Zhuang Q, Wang L, Zhan B, Du S, et al. Bone erosion in inflammatory arthritis is attenuated byTrichinella spiralis through inhibiting M1 monocyte/macrophage polarization. Iscience 2022; 25: 103979.
31
Xie X, Wu Z, Wu Y, Liu J, Chen X, Shi X, et al. Cysteine protease ofClonorchissinensis alleviates DSS-induced colitis in mice. PLOS Neglected Tropical Diseases. 2022; 16: e0010774.
32
Gryseels B, Polman K, Clerinx J, Kestens L.Human schistosomiasis. The Lancet. 2006; 368: 1106-18.
33
Cai Z, Deng X, Zhao L, Wang X, Yang L, Yuan G, et al. The relationship betweenSchistosoma and glycolipid metabolism. Microb Pathog. 2021; 159: 105120.
34
MacDonald AS, Straw AD, Bauman B, Pearce EJ. CD8− dendritic cell activation status plays an integral role in influencing Th2 response development. The J Immunol. 2001; 167: 1982-8.
35
Jankovic D, Steinfelder S, Kullberg MC, Sher A. Mechanisms underlying helminth-induced Th2 polarization: default, negative or positive pathways? Chem Immunol Allergy. 2006; 90, 65-81.
36
Cleenewerk L, Garssen J, Hogenkamp A. Clinical use ofSchistosomamansoni antigens as novel immunotherapies for autoimmune disorders. Front Immunol. 2020; 11: 1821.
37
Zinsou JF, Janse JJ, Honpkehedji YY, Dejon-Agobé JC, García-Tardón N, Hoekstra PT, et al.Schistosomahaematobium infection is associated with lower serum cholesterol levels and improved lipid profile in overweight/obese individuals. PLoS Negl Trop Dis. 2020; 14: e0008464.
38
Gao YR, Sun XZ, Li R, Tang CL, Zhang RH, Zhu YW, et al. The effect of regulatory T cells inSchistosoma-mediated protection against type 2 diabetes. Acta Tropica. 2021; 224: 106073.
39
Zhang W, Li L, Zheng Y, Xue F, Yu M, Ma Y, et al.Schistosomajaponicum peptide SJMHE1 suppresses airway inflammation of allergic asthma in mice. J Cell Mol Med. 2019; 23: 7819-29.
40
Yan K, Wang B, Zhou H, Luo Q, Shen J, Xu Y, et al. Amelioration of type 1 diabetes by recombinant fructose-1, 6-bisphosphate aldolase and cystatin derived fromSchistosomajaponicum in a murine model. ParasitolRes. 2020; 119: 203-14.
41
Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Thl-like immune responses in humans infected with Schistosomamansoni.J Infect Dis. 1996; 173: 269-72.
42
Ma Y, Wei C, Qi X, Pu Y, Dong L, Xu L, et al.Schistosomajaponicum-derived peptide SJMHE1 promotes peripheral nerve repair through a macrophage-dependent mechanism. Am J Transl Res. 2021; 13: 1290.
43
Kapczuk P, Kosik-Bogacka D, Kupnicka P, Kopytko P, Tarnowski M, Kolasa A, et al.Hymenolepisdiminuta Infection Affects Apoptosis in the Small and Large Intestine. Int J Environ Res Public Health. 2022; 19: 9753.
44
Shinoda K, Choe A, Hirahara K, Kiuchi M, Kokubo K, Ichikawa T, et al. Nematode ascarosides attenuate mammalian type 2 inflammatory responses. Proc Natl Acad Sci USA. 2022; 119: e2108686119.
45
Osbourn M, Soares DC, Vacca F, Cohen ES, Scott IC, Gregory WF, et al. HpARI protein secreted by a helminth parasite suppresses interleukin-33. Immunity. 2017; 47: 739-51.
46
Maizels RM. Ascarosides from helminths pack a punch against allergy. Proc Natl Acad Sci USA. 2022; 119: e2202250119.
47
Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun. 2012; 38: J266-74.
48
Sen A, Kushnir VA, Barad DH, Gleicher N. Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol. 2014; 10: 37-50.
49
Jiang TT, Chaturvedi V, Ertelt JM, Kinder JM, Clark DR, Valent AM, et al. Regulatory T cells: new keys for further unlocking the enigma of fetal tolerance and pregnancy complications. J Immunol. 2014; 192: 4949-56.
50
Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008; 118: 1311-21.
51
Blackwell AD, Tamayo MA, Beheim B, Trumble BC, Stieglitz J, Hooper PL, et al.Helminth infection, fecundity, and age of first pregnancy in women.Science. 2015; 350: 970-2.
52
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
53
Oliveira FMS, Cruz RE, Pinheiro GRG, Caliari MV. Comorbidities involving parasitic diseases: A look at the benefits and complications. Exp Biol Med (Maywood). 2022; 247: 15353702221108387.
54
Noya V, Bay S, Festari MF, García EP, Rodriguez E, Chiale C, et al. Mucin-like peptides from Echinococcusgranulosus induce antitumor activity. Int J Oncol. 2013; 43: 775-84.
55
Ohs I, van den Broek M, Nussbaum K, Münz C, Arnold SJ, Quezada SA, et al. Corrigendum: Interleukin-12 bypasses common gamma-chain signalling in emergency natural killer cell lymphopoiesis. Nat Commun. 2017; 8: 15185.
56
Berriel E, Russo S, Monin L, Festari MF, Berois N, Fernández G, et al. Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. ScientificWorldJournal. 2013; 230176.
57
Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol. 2001; 166: 5878-81.
58
Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J. Induction and regulation of IL-12-dependent host resistance toToxoplasmagondii. Immunol Res. 2003; 27: 521-8.
59
Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, et al. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasmagondii protects against rechallenge. J Immunol. 2013; 190: 469-78.
60
Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, et al. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One.; 6: e24407.
61
Garcia SB, Aranha AL, Garcia FRB, Basile FV, Pinto APM, Oliveira ECD, et al. A retrospective study of histopathological findings in 894 cases of megacolon: what is the relationship between megacolon and colonic cancer?. Rev Inst Med Trop Sao Paulo. 2003; 45: 91-3.
62
Abello-Cáceres P, Pizarro-Bauerle J, Rosas C, Maldonado I, Aguilar-Guzmán L, González C, et al. “Does native Trypanosomacruzi calreticulin mediate growth inhibition of a mammary tumor during infection?”. BMC Cancer. 2016; 16: 731.
63
Nagai K, Goto Y. Parasitomimetics: can we utilize parasite-derived immunomodulatory molecules for interventions to immunological disorders? Front Immunol. 2022; 13: 824695.
64
He H, Brenier-Pinchart MP, Braun L, Kraut A, Touquet B, Coute Y, et al. Characterization of aToxoplasma effector uncovers an alternative GSK3/b-catenin-regulatory pathway of inflammation. Elife 2018; 7: e39887.
65
Gay G, Braun L, Brenier-Pinchart MP, Vollaire J, Josserand V, Bertini RL, et al.Toxoplasmagondii TgIST co-opts host chromatin repressors dampening STAT1-dependent gene regulation and IFN-g–mediated host defenses. J Exp Med. 2016; 213 :1779-98.
66
Nandan D, Yi T, Lopez M, Lai C, Reiner NE.Leishmania EF-1a activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Bio Chem. 2002; 277: 50190-7.
67
Timm T, Annoscia G, Klein J, Lochnit G. The eukaryotic elongation factor 1 alpha (eEF1a) from the parasiteLeishmaniainfantum is modified with the immunomodulatory substituent phosphorylcholine (PC). Molecules. 2017; 22: 2094.
68
Rodrigues AA, Clemente TM, Dos Santos MA, Machado F.C, Gomes RG, Moreira HHT, et al. A recombinant protein based onTrypanosomacruzi P21 enhances phagocytosis. PLoS One. 2012; 7: e51384.
69
Santos MAD, Teixeira FB, Moreira HHT, Rodrigues AA, Machado FC, Clemente TM, et al. A successful strategy for the recovering of active P21, an insoluble recombinant protein ofTrypanosomacruzi. Sci Rep. 2014; 4: 4259.
70
Teixeira TL, Machado FC, Alves da Silva A, Teixeira SC, Borges BC, Dos Santos MA, et al.Trypanosoma cruzi P21: a potential novel target for chagasic cardiomyopathy therapy. Sci Rep. 2015; 5: 16877.
71
Sosoniuk E, Vallejos G, Kenawy H, Gaboriaud C, Thielens N, Fujita T, et al.Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin. Mol Immunol. 2014; 60: 80-5.
72
Park SY, Kim IS. Engulfment signals and the phagocytic machinery for apoptotic cell clearance. Exp Mol Med. 2017; 49: e331.
73
Ramírez Toloza G, Valck C, Molina MC, Ribeiro CH, López N, Sánchez G, et al.Trypanosomacruzi calreticulin: A novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiol. 2011; 216: 265-73.
